RESULTS OF a PHASE II STUDY OF BRENTUXIMAB VEDOTIN IN THE FIRST LINE TREATMENT OF HODGKIN LYMPHOMA PATIENTS CONSIDERED UNSUITABLE FOR STANDARD CHEMOTHERAPY (BREVITY). (June 2017) - Gibb, A.; Pirrie, S.; Linton, K.; Paterson, K.; Davies, A.; Collins, G.; Menne, T.; McKay, P.; Fields, P.; Miall, F.; Nagy, E.; Wheatley, K.; et al.